Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 56 IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PLASMA-LYTE 56 is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and electrolyte balance. It expands extracellular fluid volume and improves circulation by increasing plasma volume. The solution's electrolyte composition mimics plasma, helping to correct electrolyte deficits and acid-base disturbances.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Intravenous administration for fluid and electrolyte replacement in patients with deficits of water and electrolytes,Maintenance of fluid and electrolyte balance when oral intake is inadequate,Treatment of hypovolemia (low blood volume) due to various causes such as dehydration, burns, or surgery
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion; dose depends on fluid and electrolyte needs; typical adult rate: 100-200 m L/hour.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable as a fixed value; infused electrolytes distribute and are eliminated according to individual ion kinetics (e.g., sodium t½ ~30 min, chloride t½ ~1–2 h) with rapid redistribution.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
PLASMA-LYTE 56 is a crystalloid solution; its components are not metabolized. Electrolytes are distributed and eliminated via renal excretion and normal physiological pathways. The solution itself is not subject to hepatic metabolism.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Primarily renal; >90% of infused electrolytes are excreted unchanged in urine; fecal elimination negligible (<5%).
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Minimal (<5%); electrolytes (Na+, Cl-, K+, Mg2+, acetate, gluconate) are not significantly protein-bound.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Approximately 0.2–0.3 L/kg for sodium and chloride, corresponding to extracellular fluid volume; distributed throughout ECF.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
100% by intravenous route; not administered orally (bioavailability not applicable).
100% intravenous; not administered by other routes.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of potassium and magnesium accumulation; use with caution and monitor electrolytes in moderate impairment (GFR 30-59 m L/min).
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No specific adjustment required; however, monitor electrolytes in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Dose based on weight and clinical status; typical initial infusion rate: 5-10 m L/kg/hour, adjusted based on response and electrolyte monitoring.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Use with caution due to reduced renal function; start at lower infusion rates (e.g., 50-100 m L/hour) and monitor for fluid overload and electrolyte disturbances.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
No black box warning is provided for this drug.
Not applicable; no FDA boxed warning exists for this product.
Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload (e.g., congestive heart failure, pulmonary edema),Monitor electrolytes, fluid balance, and renal function during administration,Avoid in patients with hypervolemia, since this may exacerbate fluid overload conditions,Use with caution in patients receiving corticosteroids or corticotropin, as they may increase risk of fluid and electrolyte disturbances,Solutions containing acetate should be used with caution in patients with hepatic insufficiency
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hypersensitivity to any component of the solution,Clinically significant hypervolemia (fluid overload),Hyperkalemia (for solutions containing potassium),Severe renal impairment (anuria or oliguria) unless dialysis is performed,Acute or chronic metabolic alkalosis (for solutions containing acetate)
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No specific food interactions; maintain normal diet unless otherwise directed by physician. Avoid excessive potassium-rich foods if renal impairment exists.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No known teratogenic effects. Plasma-Lyte 56 is an electrolyte solution and does not cross placenta in significant amounts to cause fetal harm. Use if clearly needed.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Excreted into breast milk in negligible amounts; considered compatible with breastfeeding. M/P ratio not applicable as endogenous electrolytes.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No specific dose adjustments during pregnancy. Use standard dosing based on clinical status; avoid fluid overload in preeclampsia or cardiac conditions.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Plasma-Lyte 56 is a balanced crystalloid solution containing acetate and gluconate as buffers, which may reduce the risk of hyperchloremic metabolic acidosis compared to 0.9% saline. It is isotonic (osmolarity 406 m Osm/L) but hypotonic in plasma due to metabolism of anions, making it suitable for maintenance fluid therapy. Use caution in patients with renal impairment due to potassium content (13 m Eq/L). Not for co-administration with blood products via same tubing due to calcium content (5 m Eq/L).
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This solution provides fluids and electrolytes to maintain hydration and balance.,It contains potassium; follow dietary restrictions if you have kidney problems.,Report any signs of fluid overload (swelling, shortness of breath) or electrolyte imbalances (muscle cramps, weakness, irregular heartbeat).,Do not eat or drink anything unless instructed by your healthcare provider during infusion.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 56 IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 56 IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by PLASMA-LYTE 56 is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and electrolyte balance. It expands extracellular fluid volume and improves circulation by increasing plasma volume. The solution's electrolyte composition mimics plasma, helping to correct electrolyte deficits and acid-base disturbances.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 56 IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 56 IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs; typical adult rate: 100-200 m L/hour.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 56 IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 56 IN PLASTIC CONTAINER is classified as Category C. No known teratogenic effects. Plasma-Lyte 56 is an electrolyte solution and does not cross placenta in significant amounts to cause fetal harm. Use if clearly needed.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.